| Literature DB >> 29666440 |
Alexander Koch1, Sophie C Joosten2, Zheng Feng1, Tim C de Ruijter2, Muriel X Draht1, Veerle Melotte1, Kim M Smits1,2, Jurgen Veeck2, James G Herman3, Leander Van Neste1, Wim Van Criekinge4, Tim De Meyer5, Manon van Engeland6.
Abstract
Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in cancer, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes of this disparity, but the genomic location of a DNA methylation-based biomarker is an intrinsic and essential property that also has an important and often overlooked role. Here, we examine the importance of the location of DNA methylation for the development of cancer biomarkers, and take a detailed look at the genomic location and other relevant characteristics of the various biomarkers with commercially available tests. We also emphasize the value of publicly available databases for the development of DNA methylation-based biomarkers and the importance of accurate reporting of the full methodological details of research findings.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29666440 DOI： 10.1038/s41571-018-0004-4
Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675